Dachaigh › Myeloma iomaill › Massachusetts › Boston
Sgrùdaidhean clionaigeach Myeloma iomaill ann an Boston, MA
Tha 42 sgrùdaidhean airson Myeloma iomaill a’ lorg phàirtichean aig làraichean ann agus timcheall air Boston (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
A’ fastadhÌre 3
- Research Site, Boston
- Research Site, Boston
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 3
- Tufts Medical Center, Boston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 3
- Dana Farber Cancer Institute, Boston
- Boston University Medical Center, Boston
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
A’ fastadhÌre 3
- Dana Farber / Harvard Cancer Center, Boston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
A’ fastadhÌre 4
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
- Massachusetts General Hospital, Boston
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 1/2
- Mass General Brigham, Boston
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
A’ fastadhÌre 2
- Beth Israel Deaconess Medical Center, Boston
ELISA in Relapsed/Refractory MM
A’ fastadhÌre 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
A’ fastadhÌre 3
- Boston Medical Center, Boston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
A’ fastadhÌre 1/2
- Dana-Farber Cancer Institute /ID# 271846, Boston
Elranatamab in R/R Multiple Myeloma
A’ fastadhÌre 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Beth-Israel Deaconess Medical Center, Boston
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 1
- Dana Farber Cancer institution, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
A’ fastadhÌre 1
- Massachusetts General Hospital, Boston
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
A’ fastadhÌre 3
- Beth Israel Deaconess Medical Center, Boston
- BIDMC Research Pharmacy, Boston
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
A’ fastadhÌre 1/2
- GSK Investigational Site, Boston
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
A’ fastadhÌre 1/2
- Research Site, Boston
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
A’ fastadhÌre 3
- Tufts Medical Center, Boston
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
A’ fastadhÌre 1/2
- Boston Medical Center, Boston
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
A’ fastadhÌre 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
A’ fastadhÌre 1
- Dana-Farber Cancer Institute, Boston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
A’ fastadhÌre 1/2
- Research Site, Boston
- Research Site, Boston
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
A’ fastadhÌre 2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
A’ fastadhÌre 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Selinexor and Backbone Treatments of Multiple Myeloma Patients
A’ fastadhÌre 1/2
- Dana Farber Cancer Institute, Boston
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
A’ fastadhÌre 1
- Dana Farber/Harvard Cancer Center, Boston
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
A’ fastadh
- Dana-Farber Cancer Institute, Boston
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
A’ fastadhÌre 3
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
A’ fastadhÌre 1
- Dana Farber Cancer Institute, Boston
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
A’ fastadhÌre 1
- Beth Israel Deaconess Medical Center, Boston
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
A’ fastadhÌre 1
- Dana Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
A’ fastadh
- Massachusetts General Hospital Cancer Center, Boston
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
A’ fastadhÌre 1
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
A’ fastadhÌre 1
- Beth Israel Deaconess Medical Center, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
A’ fastadhÌre 1
- Dana-Farber Cancer Institute, Boston
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
A’ fastadh
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute, Boston
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
A’ fastadhÌre 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
A’ fastadhÌre 1/2
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
A’ fastadhSgrùdadh amharc
- Boston University Cancer Research Center, Boston
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 1/2
- Dana-Farber Cancer Institute, Boston
Sgrùdaidhean Myeloma iomaill ann am bailtean eile
- New York City, NY60 sgrùdaidhean
- Atlanta, GA41 sgrùdaidhean
- Houston, TX38 sgrùdaidhean
- Durham, NC37 sgrùdaidhean
- Nashville, TN32 sgrùdaidhean
- Denver, CO27 sgrùdaidhean
- Rochester, MN24 sgrùdaidhean
- St. Louis, MO24 sgrùdaidhean
- Columbus, OH24 sgrùdaidhean
- Baldwin Park, CA23 sgrùdaidhean
- Chicago, IL22 sgrùdaidhean
- Seattle, WA22 sgrùdaidhean
Sgrùdaidhean eile ann an Boston
- Aillse a' bhroilleach111 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag90 sgrùdaidhean
- Aillse (gach seòrsa)86 sgrùdaidhean
- Aillse colorectal63 sgrùdaidhean
- Ailse metastatach63 sgrùdaidhean
- Ailseachadh nan Sgamhan62 sgrùdaidhean
- Cancer Ovarian61 sgrùdaidhean
- Aillse Prostata59 sgrùdaidhean
- Depression52 sgrùdaidhean
- Ailse Endometrial50 sgrùdaidhean
- Fàilligeadh a' Chridhe44 sgrùdaidhean
- Leukemia myeloid geur44 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.